<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742114</url>
  </required_header>
  <id_info>
    <org_study_id>QiluH 2020039123</org_study_id>
    <nct_id>NCT04742114</nct_id>
  </id_info>
  <brief_title>Effect of EPAP Device on Emphysema and Lung Bullae</brief_title>
  <official_title>Effect of EPAP Device on Emphysema and Lung Bullae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and the effects and of the application of&#xD;
      Expiratory Positive Airway Pressure (EPAP) device on Dynamic Hyperinflation and dyspnea in&#xD;
      patients with Emphysema and pulmonary bullae.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will last for six months. Patients will be collected clinical and anthropometric&#xD;
      data by using questionnaires initially. Patients will have the pulmonary function test and CT&#xD;
      scan and conduct 6MWT every two months. And Borg scale data will be collected every two&#xD;
      months. The application of EPAP (15cmH2O) via face mask will be randomized with the help of&#xD;
      opaque envelopes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2021</start_date>
  <completion_date type="Anticipated">February 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The subjects were divided into two groups. The first group use the breathing mask without the positive pressure valve, and the second group use the breathing mask with a positive pressure valve, that is EPAP breathing mask.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CT DICOM data</measure>
    <time_frame>Change from Baseline CT attenuation value at 6 months.</time_frame>
    <description>Quantitative analysis of emphysema severity will be performed on segmented lung images by using the Slicer software package. The total emphysema percentage will be defined as all lung voxels with a CT attenuation value of less than - 910 HU.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FVC in pulmonary function test</measure>
    <time_frame>Change from Baseline FVC data at 2 months.</time_frame>
    <description>The data of the patient's FVC will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC in pulmonary function test</measure>
    <time_frame>Change from Baseline FVC data at 4 months.</time_frame>
    <description>The data of the patient's FVC will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC in pulmonary function test</measure>
    <time_frame>Change from Baseline FVC data at 6 months.</time_frame>
    <description>The data of the patient's FVC will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC% in pulmonary function test</measure>
    <time_frame>Change from Baseline FVC% data at 2 months.</time_frame>
    <description>The data of the patient's FVC% will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC% in pulmonary function test</measure>
    <time_frame>Change from Baseline FVC% data at 4 months.</time_frame>
    <description>The data of the patient's FVC% will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC% in pulmonary function test</measure>
    <time_frame>Change from Baseline FVC% data at 6 months.</time_frame>
    <description>The data of the patient's FVC% will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 in pulmonary function test</measure>
    <time_frame>Change from Baseline FEV1 data at 2 months.</time_frame>
    <description>The data of the patient's FEV1 will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 in pulmonary function test</measure>
    <time_frame>Change from Baseline FEV1 data at 4 months.</time_frame>
    <description>The data of the patient's FEV1 will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 in pulmonary function test</measure>
    <time_frame>Change from Baseline FEV1 data at 6 months.</time_frame>
    <description>The data of the patient's FEV1 will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1% in pulmonary function test</measure>
    <time_frame>Change from Baseline FEV1% data at 2 months.</time_frame>
    <description>The data of the patient's FEV1% will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1% in pulmonary function test</measure>
    <time_frame>Change from Baseline FEV1% data at 4 months.</time_frame>
    <description>The data of the patient's FEV1% will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1% in pulmonary function test</measure>
    <time_frame>Change from Baseline FEV1% data at 6 months.</time_frame>
    <description>The data of the patient's FEV1% will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/ FVC% in pulmonary function test</measure>
    <time_frame>Change from Baseline FEV1/ FVC% data at 2 months.</time_frame>
    <description>The data of the patient's FEV1/ FVC% will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/ FVC% in pulmonary function test</measure>
    <time_frame>Change from Baseline FEV1/ FVC% data at 4 months.</time_frame>
    <description>The data of the patient's FEV1/ FVC% will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/ FVC% in pulmonary function test</measure>
    <time_frame>Change from Baseline FEV1/ FVC% data at 6 months.</time_frame>
    <description>The data of the patient's FEV1/ FVC% will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLC in pulmonary function test</measure>
    <time_frame>Change from Baseline TLC data at 2 months.</time_frame>
    <description>The data of the patient's TLC will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLC in pulmonary function test</measure>
    <time_frame>Change from Baseline TLC data at 4 months.</time_frame>
    <description>The data of the patient's TLC will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLC in pulmonary function test</measure>
    <time_frame>Change from Baseline TLC data at 6 months.</time_frame>
    <description>The data of the patient's TLC will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV/TLC in pulmonary function test</measure>
    <time_frame>Change from Baseline RV/TLC data at 2 months.</time_frame>
    <description>The data of the patient's RV/TLC will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV/TLC in pulmonary function test</measure>
    <time_frame>Change from Baseline RV/TLC data at 4 months.</time_frame>
    <description>The data of the patient's RV/TLC will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV/TLC in pulmonary function test</measure>
    <time_frame>Change from Baseline RV/TLC data at 6 months.</time_frame>
    <description>The data of the patient's RV/TLC will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FRC in pulmonary function test</measure>
    <time_frame>Change from Baseline FRC data at 2 months.</time_frame>
    <description>The data of the patient's FRC will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FRC in pulmonary function test</measure>
    <time_frame>Change from Baseline FRC data at 4 months.</time_frame>
    <description>The data of the patient's FRC will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FRC in pulmonary function test</measure>
    <time_frame>Change from Baseline FRC data at 6 months.</time_frame>
    <description>The data of the patient's FRC will be collected to evaluate the change of the patient's lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ETCO2</measure>
    <time_frame>Change from Baseline ETCO2 data at 2 months during the intervention.</time_frame>
    <description>ETCO2 data will be collected to assess changes in CO2 retention in patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ETCO2</measure>
    <time_frame>Change from Baseline ETCO2 data at 4 months during the intervention.</time_frame>
    <description>ETCO2 data will be collected to assess changes in CO2 retention in patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ETCO2</measure>
    <time_frame>Change from Baseline ETCO2 data at 6 months during the intervention.</time_frame>
    <description>ETCO2 data will be collected to assess changes in CO2 retention in patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minutes walk test(6MWT)</measure>
    <time_frame>Change from Baseline 6MWT data at 2 months during the intervention.</time_frame>
    <description>The 6 minutes walk test data will be collected to assess the cardiopulmonary function of the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minutes walk test(6MWT)</measure>
    <time_frame>Change from Baseline 6MWT data at 4 months during the intervention.</time_frame>
    <description>The 6 minutes walk test data will be collected to assess the cardiopulmonary function of the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minutes walk test(6MWT)</measure>
    <time_frame>Change from Baseline 6MWT data at 6 months during the intervention.</time_frame>
    <description>The 6 minutes walk test data will be collected to assess the cardiopulmonary function of the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg scale score</measure>
    <time_frame>Change from Baseline Borg scale score data at 2 months during the intervention.</time_frame>
    <description>The Borg scale data will be collected to assess changes in dyspnea.The scale scores range from 0 to 10, with 0 indicating the minimum and 10 indicating the maximum. The higher the score, the more severe the dyspnea is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg scale score</measure>
    <time_frame>Change from Baseline Borg scale score data at 4 months during the intervention.</time_frame>
    <description>The Borg scale data will be collected to assess changes in dyspnea.The scale scores range from 0 to 10, with 0 indicating the minimum and 10 indicating the maximum. The higher the score, the more severe the dyspnea is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg scale score</measure>
    <time_frame>Change from Baseline Borg scale score data at 6 months during the intervention.</time_frame>
    <description>The Borg scale data will be collected to assess changes in dyspnea.The scale scores range from 0 to 10, with 0 indicating the minimum and 10 indicating the maximum. The higher the score, the more severe the dyspnea is.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Emphysema</condition>
  <condition>Bullous Disease Lung</condition>
  <arm_group>
    <arm_group_label>the face mask without EPAP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Will be collected clinical and anthropometric data of the participant. Will have the pulmonary function test every two months. Will be collected CT scan data. Patients will conduct 6MWT every two months. Borg scale data will be collected.The face mask without the application of EPAP will be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the face mask with EPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will be collected clinical and anthropometric data of the participant. Will have the pulmonary function test every two months. Will be collected CT scan data. Patients will conduct 6MWT every two months. Borg scale data will be collected.The application of EPAP (15cmH2O) via face mask will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>use the face mask with Expiratory Positive Airway Pressure(EPAP).</intervention_name>
    <description>The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.</description>
    <arm_group_label>the face mask with EPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>use the face mask without Expiratory Positive Airway Pressure(EPAP).</intervention_name>
    <description>The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.</description>
    <arm_group_label>the face mask without EPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient was ≤65 years old&#xD;
&#xD;
          -  CT examination revealed emphysema (absolute CT value ≥910) or bullae&#xD;
&#xD;
          -  CT do not show other imaging changes of lung diseases, such as mass, exudation and&#xD;
             interstitial changes&#xD;
&#xD;
          -  No history of lung cancer, pneumonectomy, any history of cystic fibrosis, allergic&#xD;
             alveolitis, or pulmonary fibrosis&#xD;
&#xD;
          -  Patients volunteer to participate and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with asthma, bronchiectasis, interstitial lung disease and other basic lung&#xD;
             diseases&#xD;
&#xD;
          -  Patients with heart failure&#xD;
&#xD;
          -  Patients with a history of malignancy&#xD;
&#xD;
          -  Patients are reluctant to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>dedong ma, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>dedong ma, Doctor</last_name>
    <phone>82169333</phone>
    <email>ma@qiluhuxi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>zhaoning xu, PostGraduate</last_name>
    <phone>17863944852</phone>
    <email>1294244479@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dedong Ma, Doctor</last_name>
      <phone>18560082806</phone>
      <email>ma@qiluhuxi.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhaoning Xu, bachelor</last_name>
      <phone>17863944852</phone>
      <email>1294244479@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhaoning Xu, bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Huang K, Yao W, Sun T, Shan G, Yang T, Lin Y, Wu S, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Zhou Y, Ding L, Yang T, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Chen CS, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Cao B, Dai H, Liang L, He J; China Pulmonary Health Study Group. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018 Apr 28;391(10131):1706-1717. doi: 10.1016/S0140-6736(18)30841-9. Epub 2018 Apr 9.</citation>
    <PMID>29650248</PMID>
  </reference>
  <reference>
    <citation>Ranieri VM, Giuliani R, Cinnella G, Pesce C, Brienza N, Ippolito EL, Pomo V, Fiore T, Gottfried SB, Brienza A. Physiologic effects of positive end-expiratory pressure in patients with chronic obstructive pulmonary disease during acute ventilatory failure and controlled mechanical ventilation. Am Rev Respir Dis. 1993 Jan;147(1):5-13.</citation>
    <PMID>8420430</PMID>
  </reference>
  <reference>
    <citation>Fagevik Olsén M, Lannefors L, Westerdahl E. Positive expiratory pressure - Common clinical applications and physiological effects. Respir Med. 2015 Mar;109(3):297-307. doi: 10.1016/j.rmed.2014.11.003. Epub 2014 Nov 12. Review.</citation>
    <PMID>25573419</PMID>
  </reference>
  <reference>
    <citation>Blanch L, Bernabé F, Lucangelo U. Measurement of air trapping, intrinsic positive end-expiratory pressure, and dynamic hyperinflation in mechanically ventilated patients. Respir Care. 2005 Jan;50(1):110-23; discussion 123-4. Review.</citation>
    <PMID>15636649</PMID>
  </reference>
  <reference>
    <citation>Kondili E, Alexopoulou C, Prinianakis G, Xirouchaki N, Georgopoulos D. Pattern of lung emptying and expiratory resistance in mechanically ventilated patients with chronic obstructive pulmonary disease. Intensive Care Med. 2004 Jul;30(7):1311-8. Epub 2004 Mar 31. Erratum in: Intensive Care Med. 2004 Nov;30(11):2140.</citation>
    <PMID>15054570</PMID>
  </reference>
  <reference>
    <citation>Gosselink R. Controlled breathing and dyspnea in patients with chronic obstructive pulmonary disease (COPD). J Rehabil Res Dev. 2003 Sep-Oct;40(5 Suppl 2):25-33. Review.</citation>
    <PMID>15074451</PMID>
  </reference>
  <reference>
    <citation>Dechman G, Wilson CR. Evidence underlying breathing retraining in people with stable chronic obstructive pulmonary disease. Phys Ther. 2004 Dec;84(12):1189-97. Review.</citation>
    <PMID>15563259</PMID>
  </reference>
  <reference>
    <citation>Puente-Maestu L, Stringer WW. Hyperinflation and its management in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(4):381-400. Review.</citation>
    <PMID>18044095</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Emphysema</keyword>
  <keyword>Bullous</keyword>
  <keyword>Expiratory Positive Airway Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

